Yingzhou Lu

Yingzhou Lu, Lulu Chen, Yuanyuan Zhang et al.

Machine learning heavily relies on data, but real-world applications often encounter various data-related issues. These include data of poor quality, insufficient data points leading to under-fitting of machine learning models, and difficulties in data access due to concerns surrounding privacy, safety, and regulations. In light of these challenges, the concept of synthetic data generation emerges as a promising alternative that allows for data sharing and utilization in ways that real-world data cannot facilitate. This paper presents a comprehensive systematic review of existing studies that employ machine learning models for the purpose of generating synthetic data. The review encompasses various perspectives, starting with the applications of synthetic data generation, spanning computer vision, speech, natural language processing, healthcare, and business domains. Additionally, it explores different machine learning methods, with particular emphasis on neural network architectures and deep generative models. The paper also addresses the crucial aspects of privacy and fairness concerns related to synthetic data generation. Furthermore, this study identifies the challenges and opportunities prevalent in this emerging field, shedding light on the potential avenues for future research. By delving into the intricacies of synthetic data generation, this paper aims to contribute to the advancement of knowledge and inspire further exploration in synthetic data generation.

Yingzhou Lu, Kosaku Sato, Jialu Wang

With the rise of internet technology amidst increasing rates of urbanization, sharing information has never been easier thanks to globally-adopted platforms for digital communication. The resulting output of massive amounts of user-generated data can be used to enhance our understanding of significant societal issues particularly for urbanizing areas. In order to better analyze protest behavior, we enhanced the GSR dataset and manually labeled all the images. We used deep learning techniques to analyze social media data to detect social unrest through image classification, which performed good in predict multi-attributes, then also used map visualization to display protest behaviors across the country.

Bohao Xu, Yingzhou Lu, Chenhao Li et al.

In drug discovery, predicting the absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of small-molecule drugs is critical for ensuring safety and efficacy. However, the process of accurately predicting these properties is often resource-intensive and requires extensive experimental data. To address this challenge, we propose SMILES-Mamba, a two-stage model that leverages both unlabeled and labeled data through a combination of self-supervised pretraining and fine-tuning strategies. The model first pre-trains on a large corpus of unlabeled SMILES strings to capture the underlying chemical structure and relationships, before being fine-tuned on smaller, labeled datasets specific to ADMET tasks. Our results demonstrate that SMILES-Mamba exhibits competitive performance across 22 ADMET datasets, achieving the highest score in 14 tasks, highlighting the potential of self-supervised learning in improving molecular property prediction. This approach not only enhances prediction accuracy but also reduces the dependence on large, labeled datasets, offering a promising direction for future research in drug discovery.

Wanghan Xu, Yuhao Zhou, Yifan Zhou et al.

Despite advances in scientific AI, a coherent framework for Scientific General Intelligence (SGI)-the ability to autonomously conceive, investigate, and reason across scientific domains-remains lacking. We present an operational SGI definition grounded in the Practical Inquiry Model (PIM: Deliberation, Conception, Action, Perception) and operationalize it via four scientist-aligned tasks: deep research, idea generation, dry/wet experiments, and experimental reasoning. SGI-Bench comprises over 1,000 expert-curated, cross-disciplinary samples inspired by Science's 125 Big Questions, enabling systematic evaluation of state-of-the-art LLMs. Results reveal gaps: low exact match (10--20%) in deep research despite step-level alignment; ideas lacking feasibility and detail; high code executability but low execution result accuracy in dry experiments; low sequence fidelity in wet protocols; and persistent multimodal comparative-reasoning challenges. We further introduce Test-Time Reinforcement Learning (TTRL), which optimizes retrieval-augmented novelty rewards at inference, enhancing hypothesis novelty without reference answer. Together, our PIM-grounded definition, workflow-centric benchmark, and empirical insights establish a foundation for AI systems that genuinely participate in scientific discovery.

Ling Yue, Sixue Xing, Yingzhou Lu et al.

The advancement of natural language processing (NLP) in biology hinges on models' ability to interpret intricate biomedical literature. Traditional models often struggle with the complex and domain-specific language in this field. In this paper, we present BioMamba, a pre-trained model specifically designed for biomedical text mining. BioMamba builds upon the Mamba architecture and is pre-trained on an extensive corpus of biomedical literature. Our empirical studies demonstrate that BioMamba significantly outperforms models like BioBERT and general-domain Mamba across various biomedical tasks. For instance, BioMamba achieves a 100 times reduction in perplexity and a 4 times reduction in cross-entropy loss on the BioASQ test set. We provide an overview of the model architecture, pre-training process, and fine-tuning techniques. Additionally, we release the code and trained model to facilitate further research.

Yingzhou Lu, Yaojun Hu, Chenhao Li

Bringing a novel drug from the original idea to market typically requires more than ten years and billions of dollars. To alleviate the heavy burden, a natural idea is to reuse the approved drug to treat new diseases. The process is also known as drug repurposing or drug repositioning. Machine learning methods exhibited huge potential in automating drug repurposing. However, it still encounter some challenges, such as lack of labels and multimodal feature representation. To address these issues, we design DrugCLIP, a cutting-edge contrastive learning method, to learn drug and disease's interaction without negative labels. Additionally, we have curated a drug repurposing dataset based on real-world clinical trial records. Thorough empirical studies are conducted to validate the effectiveness of the proposed DrugCLIP method.

Bohao Xu, Yingzhou Lu, Yoshitaka Inoue et al.

Protein function prediction is a pivotal task in drug discovery, significantly impacting the development of effective and safe therapeutics. Traditional machine learning models often struggle with the complexity and variability inherent in predicting protein functions, necessitating more sophisticated approaches. In this work, we introduce Protein-Mamba, a novel two-stage model that leverages both self-supervised learning and fine-tuning to improve protein function prediction. The pre-training stage allows the model to capture general chemical structures and relationships from large, unlabeled datasets, while the fine-tuning stage refines these insights using specific labeled datasets, resulting in superior prediction performance. Our extensive experiments demonstrate that Protein-Mamba achieves competitive performance, compared with a couple of state-of-the-art methods across a range of protein function datasets. This model's ability to effectively utilize both unlabeled and labeled data highlights the potential of self-supervised learning in advancing protein function prediction and offers a promising direction for future research in drug discovery.

Yinlong Xu, Xiaoqiang Liu, Zitai Kong et al.

Cardiac arrhythmia, a condition characterized by irregular heartbeats, often serves as an early indication of various heart ailments. With the advent of deep learning, numerous innovative models have been introduced for diagnosing arrhythmias using Electrocardiogram (ECG) signals. However, recent studies solely focus on the performance of models, neglecting the interpretation of their results. This leads to a considerable lack of transparency, posing a significant risk in the actual diagnostic process. To solve this problem, this paper introduces MambaCapsule, a deep neural networks for ECG arrhythmias classification, which increases the explainability of the model while enhancing the accuracy.Our model utilizes Mamba for feature extraction and Capsule networks for prediction, providing not only a confidence score but also signal features. Akin to the processing mechanism of human brain, the model learns signal features and their relationship between them by reconstructing ECG signals in the predicted selection. The model evaluation was conducted on MIT-BIH and PTB dataset, following the AAMI standard. MambaCapsule has achieved a total accuracy of 99.54% and 99.59% on the test sets respectively. These results demonstrate the promising performance of under the standard test protocol.

Yuxuan Lu, Ziyi Wang, Yingzhou Lu et al.

Training tool-calling agents requires large-scale trajectory data with verifiable labels, yet existing approaches either synthesize environments that diverge from real API behavior or generate tasks without ground-truth outcomes for verification. We present FireFly, a pipeline for generating verified tool-call data from real-world MCP servers. Our key insight is to invert the standard synthesis pipeline: rather than generating tasks and hoping they are solvable, we first let a strong LLM explore real APIs along graph-guided DAG structures, then synthesize tasks backward from observed outcomes, guaranteeing label correctness by construction. To handle the scale of real-world tool spaces (${\sim}$1,000 tools), we build a pairwise tool graph and sample sub-DAGs to focus exploration on semantically coherent workflows. To address environment drift in live APIs, we construct a retrieval-augmented simulator that caches all exploration results and replays them during training and evaluation, enabling fully offline and reproducible RL. Applying this pipeline yields 5,144 verified tasks spanning 240 servers and 993 tools. A 4B-parameter model trained with GRPO on FireFly matches Claude Sonnet 4.6 on our held-out test set and shows improvements on multiple tool-calling benchmarks including Tau2-Bench, MCPMark, and MCP-Atlas.

Yingzhou Lu, Minjie Shen, Ling Yue et al.

The surge in high-throughput omics data has reshaped the landscape of biological research, underlining the need for powerful, user-friendly data analysis and interpretation tools. This paper presents GenoCraft, a web-based comprehensive software solution designed to handle the entire pipeline of omics data processing. GenoCraft offers a unified platform featuring advanced bioinformatics tools, covering all aspects of omics data analysis. It encompasses a range of functionalities, such as normalization, quality control, differential analysis, network analysis, pathway analysis, and diverse visualization techniques. This software makes state-of-the-art omics data analysis more accessible to a wider range of users. With GenoCraft, researchers and data scientists have access to an array of cutting-edge bioinformatics tools under a user-friendly interface, making it a valuable resource for managing and analyzing large-scale omics data. The API with an interactive web interface is publicly available at https://genocraft.stanford. edu/. We also release all the codes in https://github.com/futianfan/GenoCraft.

Chris Zhuang, Debadyuti Mukherjee, Yingzhou Lu et al.

Molecular discovery has brought great benefits to the chemical industry. Various molecule design techniques are developed to identify molecules with desirable properties. Traditional optimization methods, such as genetic algorithms, continue to achieve state-of-the-art results across multiple molecular design benchmarks. However, these techniques rely solely on random walk exploration, which hinders both the quality of the final solution and the convergence speed. To address this limitation, we propose a novel approach called Gradient Genetic Algorithm (Gradient GA), which incorporates gradient information from the objective function into genetic algorithms. Instead of random exploration, each proposed sample iteratively progresses toward an optimal solution by following the gradient direction. We achieve this by designing a differentiable objective function parameterized by a neural network and utilizing the Discrete Langevin Proposal to enable gradient guidance in discrete molecular spaces. Experimental results demonstrate that our method significantly improves both convergence speed and solution quality, outperforming cutting-edge techniques. For example, it achieves up to a 25% improvement in the top-10 score over the vanilla genetic algorithm. The code is publicly available at https://github.com/debadyuti23/GradientGA.

Kangyu Zheng, Yingzhou Lu, Zaixi Zhang et al.

Currently, the field of structure-based drug design is dominated by three main types of algorithms: search-based algorithms, deep generative models, and reinforcement learning. While existing works have typically focused on comparing models within a single algorithmic category, cross-algorithm comparisons remain scarce. In this paper, to fill the gap, we establish a benchmark to evaluate the performance of sixteen models across these different algorithmic foundations by assessing the pharmaceutical properties of the generated molecules and their docking affinities with specified target proteins. We highlight the unique advantages of each algorithmic approach and offer recommendations for the design of future SBDD models. We emphasize that 1D/2D ligand-centric drug design methods can be used in SBDD by treating the docking function as a black-box oracle, which is typically neglected. The empirical results show that 1D/2D methods achieve competitive performance compared with 3D-based methods that use the 3D structure of the target protein explicitly. Also, AutoGrow4, a 2D molecular graph-based genetic algorithm, dominates SBDD in terms of optimization ability. The relevant code is available in https://github.com/zkysfls/2024-sbdd-benchmark.

Yue Wang, Tianfan Fu, Yinlong Xu et al.

Clinical trials are indispensable for medical research and the development of new treatments. However, clinical trials often involve thousands of participants and can span several years to complete, with a high probability of failure during the process. Recently, there has been a burgeoning interest in virtual clinical trials, which simulate real-world scenarios and hold the potential to significantly enhance patient safety, expedite development, reduce costs, and contribute to the broader scientific knowledge in healthcare. Existing research often focuses on leveraging electronic health records (EHRs) to support clinical trial outcome prediction. Yet, trained with limited clinical trial outcome data, existing approaches frequently struggle to perform accurate predictions. Some research has attempted to generate EHRs to augment model development but has fallen short in personalizing the generation for individual patient profiles. Recently, the emergence of large language models has illuminated new possibilities, as their embedded comprehensive clinical knowledge has proven beneficial in addressing medical issues. In this paper, we propose a large language model-based digital twin creation approach, called TWIN-GPT. TWIN-GPT can establish cross-dataset associations of medical information given limited data, generating unique personalized digital twins for different patients, thereby preserving individual patient characteristics. Comprehensive experiments show that using digital twins created by TWIN-GPT can boost the clinical trial outcome prediction, exceeding various previous prediction approaches.

Tianyi Chen, Yingzhou Lu, Nan Hao et al.

The importance of uncertainty quantification is increasingly recognized in the diverse field of machine learning. Accurately assessing model prediction uncertainty can help provide deeper understanding and confidence for researchers and practitioners. This is especially critical in medical diagnosis and drug discovery areas, where reliable predictions directly impact research quality and patient health. In this paper, we proposed incorporating uncertainty quantification into clinical trial outcome predictions. Our main goal is to enhance the model's ability to discern nuanced differences, thereby significantly improving its overall performance. We have adopted a selective classification approach to fulfill our objective, integrating it seamlessly with the Hierarchical Interaction Network (HINT), which is at the forefront of clinical trial prediction modeling. Selective classification, encompassing a spectrum of methods for uncertainty quantification, empowers the model to withhold decision-making in the face of samples marked by ambiguity or low confidence, thereby amplifying the accuracy of predictions for the instances it chooses to classify. A series of comprehensive experiments demonstrate that incorporating selective classification into clinical trial predictions markedly enhances the model's performance, as evidenced by significant upticks in pivotal metrics such as PR-AUC, F1, ROC-AUC, and overall accuracy. Specifically, the proposed method achieved 32.37\%, 21.43\%, and 13.27\% relative improvement on PR-AUC over the base model (HINT) in phase I, II, and III trial outcome prediction, respectively. When predicting phase III, our method reaches 0.9022 PR-AUC scores. These findings illustrate the robustness and prospective utility of this strategy within the area of clinical trial predictions, potentially setting a new benchmark in the field.

Sizhe Liu, Yizhou Lu, Siyu Chen et al.

Recent progress in Large Language Models (LLMs) has drawn attention to their potential for accelerating drug discovery. However, a central problem remains: translating theoretical ideas into robust implementations in the highly specialized context of pharmaceutical research. This limitation prevents practitioners from making full use of the latest AI developments in drug discovery. To address this challenge, we introduce DrugAgent, a multi-agent framework that automates machine learning (ML) programming for drug discovery tasks. DrugAgent employs an LLM Planner that formulates high-level ideas and an LLM Instructor that identifies and integrates domain knowledge when implementing those ideas. We present case studies on three representative drug discovery tasks. Our results show that DrugAgent consistently outperforms leading baselines, including a relative improvement of 4.92% in ROC-AUC compared to ReAct for drug-target interaction (DTI). DrugAgent is publicly available at https://anonymous.4open.science/r/drugagent-5C42/.

Lincan Li, Jiaqi Li, Catherine Chen et al.

In recent years, large language models (LLMs) have been widely adopted in political science tasks such as election prediction, sentiment analysis, policy impact assessment, and misinformation detection. Meanwhile, the need to systematically understand how LLMs can further revolutionize the field also becomes urgent. In this work, we--a multidisciplinary team of researchers spanning computer science and political science--present the first principled framework termed Political-LLM to advance the comprehensive understanding of integrating LLMs into computational political science. Specifically, we first introduce a fundamental taxonomy classifying the existing explorations into two perspectives: political science and computational methodologies. In particular, from the political science perspective, we highlight the role of LLMs in automating predictive and generative tasks, simulating behavior dynamics, and improving causal inference through tools like counterfactual generation; from a computational perspective, we introduce advancements in data preparation, fine-tuning, and evaluation methods for LLMs that are tailored to political contexts. We identify key challenges and future directions, emphasizing the development of domain-specific datasets, addressing issues of bias and fairness, incorporating human expertise, and redefining evaluation criteria to align with the unique requirements of computational political science. Political-LLM seeks to serve as a guidebook for researchers to foster an informed, ethical, and impactful use of Artificial Intelligence in political science. Our online resource is available at: http://political-llm.org/.

Ming Hu, Chenglong Ma, Wei Li et al. · pku

Scientific Large Language Models (Sci-LLMs) are transforming how knowledge is represented, integrated, and applied in scientific research, yet their progress is shaped by the complex nature of scientific data. This survey presents a comprehensive, data-centric synthesis that reframes the development of Sci-LLMs as a co-evolution between models and their underlying data substrate. We formulate a unified taxonomy of scientific data and a hierarchical model of scientific knowledge, emphasizing the multimodal, cross-scale, and domain-specific challenges that differentiate scientific corpora from general natural language processing datasets. We systematically review recent Sci-LLMs, from general-purpose foundations to specialized models across diverse scientific disciplines, alongside an extensive analysis of over 270 pre-/post-training datasets, showing why Sci-LLMs pose distinct demands -- heterogeneous, multi-scale, uncertainty-laden corpora that require representations preserving domain invariance and enabling cross-modal reasoning. On evaluation, we examine over 190 benchmark datasets and trace a shift from static exams toward process- and discovery-oriented assessments with advanced evaluation protocols. These data-centric analyses highlight persistent issues in scientific data development and discuss emerging solutions involving semi-automated annotation pipelines and expert validation. Finally, we outline a paradigm shift toward closed-loop systems where autonomous agents based on Sci-LLMs actively experiment, validate, and contribute to a living, evolving knowledge base. Collectively, this work provides a roadmap for building trustworthy, continually evolving artificial intelligence (AI) systems that function as a true partner in accelerating scientific discovery.

Xiangrui Liu, Yuanyuan Zhang, Qianyu Shang et al.

Foundation models, first introduced in 2021, refer to large-scale pretrained models (e.g., large language models (LLMs) and vision-language models (VLMs)) that learn from extensive unlabeled datasets through unsupervised methods, enabling them to excel in diverse downstream tasks. These models, like GPT, can be adapted to various applications such as question answering and visual understanding, outperforming task-specific AI models and earning their name due to broad applicability across fields. The development of biomedical foundation models marks a significant milestone in the use of artificial intelligence (AI) to understand complex biological phenomena and advance medical research and practice. This survey explores the potential of foundation models in diverse domains within biomedical fields, including computational biology, drug discovery and development, clinical informatics, medical imaging, and public health. The purpose of this survey is to inspire ongoing research in the application of foundation models to health science.

Qun Wang, Yingzhou Lu, Guiran Liu et al.

Unlicensed 6GHz is becoming a primary workhorse for high-capacity access, with Wi-Fi and 5G NR-U competing for the same channels under listen-before-talk (LBT) rules. Operating in this regime requires decisions that jointly trade throughput, energy, and service-level objectives while remaining safe and auditable. We present an agentic controller that separates {policy} from {execution}. At the start of each scheduling epoch the agent summarizes telemetry (per-channel busy and baseline LBT failure; per-user CQI, backlog, latency, battery, priority, and power mode) and invokes a large language model (LLM) to propose a small set of interpretable knobs: a fairness index α, per-channel duty-cycle caps for Wi-Fi/NR-U, and class weights. A deterministic optimizer then enforces feasibility and computes an α-fair allocation that internalizes LBT losses and energy cost; malformed or unsafe policies are clamped and fall back to a rule baseline. In a 6GHz simulator with two 160MHz channels and mixed Wi-Fi/NR-U users, LLM-assisted policies consistently improve energy efficiency while keeping throughput competitive with a strong rule baseline. One LLM lowers total energy by 35.3% at modest throughput loss, and another attains the best overall trade-off, finishing with higher total bits (+3.5%) and higher bits/J (+12.2%) than the baseline. We release code, per-epoch logs, and plotting utilities to reproduce all figures and numbers, illustrating how transparent, policy-level LLM guidance can safely improve wireless coexistence.

Jintai Chen, Yaojun Hu, Mingchen Cai et al.

Clinical trials are pivotal for developing new medical treatments but typically carry risks such as patient mortality and enrollment failure that waste immense efforts spanning over a decade. Applying artificial intelligence (AI) to predict key events in clinical trials holds great potential for providing insights to guide trial designs. However, complex data collection and question definition requiring medical expertise have hindered the involvement of AI thus far. This paper tackles these challenges by presenting a comprehensive suite of 23 meticulously curated AI-ready datasets covering multi-modal input features and 8 crucial prediction challenges in clinical trial design, encompassing prediction of trial duration, patient dropout rate, serious adverse event, mortality rate, trial approval outcome, trial failure reason, drug dose finding, design of eligibility criteria. Furthermore, we provide basic validation methods for each task to ensure the datasets' usability and reliability. We anticipate that the availability of such open-access datasets will catalyze the development of advanced AI approaches for clinical trial design, ultimately advancing clinical trial research and accelerating medical solution development.